Market Excitement Builds: XRP, DOGE, ADA Surge Before Trump’s Nashville Speech

Bitget

News

Coinedition2024/07/27 15:37

By:Abdulkarim Abdulwahab

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Donald Trump’s upcoming speech at Bitcoin 2024 sparks a crypto market rally, with BTC reclaiming $68K.
Cardano is up 2%, Dogecoin has risen 3.66%, and XRP has increased by 1%.
Crypto advocates hope Trump will announce plans for a U.S. strategic Bitcoin reserve.

With the former U.S. President Donald Trump set to speak at the Bitcoin 2024 conference in Nashville, Tennessee, the crypto market has responded with a price boom. Bitcoin surged past $68,000 as of writing, while other major cryptocurrencies also saw significant gains. Cardano (ADA) was up 2%, Dogecoin (DOGE) rose 3.66%, and XRP increased by 1%.

This rally seems to be driven by hopes that Trump will make a positive announcement about cryptocurrency, potentially sparking broader growth in the industry. Many speculate that Trump will discuss plans for the U.S. government to establish a strategic Bitcoin reserve. Others hope he will reiterate his views about wanting Bitcoin to be “made in America.” Fred Thiel, CEO of Bitcoin miner Marathon Digital, remarked:

“If the U.S. were to have a strategic reserve for Bitcoin, they could project power. The U.S. needs to be the largest holder of Bitcoin and the largest miner of Bitcoin.”

Michelle Bond, a former political candidate and crypto advocate, hopes Trump will detail his plans to keep the industry onshore and make the U.S. a leader in the space. She also suggests he consider appointing a “crypto czar” to coordinate regulatory efforts and promote a positive tone towards cryptocurrency.

Meanwhile, not everyone is excited about Trump’s upcoming speech on crypto. Bittrex Global CEO Oliver Linch took a more laid-back approach, stating that the Trump’ address is newsworthy in itself. Others, like retired software developer Phil Whatley, hope Trump will clarify on whether Bitcoin transactions would become tax-free.

While the market’s precise reaction to Donald Trump’s speech remains uncertain, the pre-keynote price surge suggests a bullish sentiment. Investors may be anticipating a positive message that could propel the market to new all-time highs.

Disclaimer: The information presented in this article is for informational and educational purposes only. The article does not constitute financial advice or advice of any kind. Coin Edition is not responsible for any losses incurred as a result of the utilization of content, products, or services mentioned. Readers are advised to exercise caution before taking any action related to the company.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Trump Media Stock (DJT) Plunge Destroys $2.2 Billion in Retail Wealth as Donald Trump Keeps $460 Million Stake

Tipranks•2026/11/06 13:39

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37